Mounjaro Beats Ozempic in Head-to-Head Study

Why did UnitedHealth's CEO resign abruptly? How will the U.S.-China tariff truce impact imports? What caused Coinbase's stock to jump recently? Why is Honda delaying its EV project in Canada? How did Nvidia’s Saudi AI deal affect its stock? What are the implications of Trump lifting Syria sanctions? Why is Microsoft cutting 3% of its workforce? How is the U.S.-Saudi $600B investment deal structured? What effect did tariff cuts have on U.S. inflation?

Mounjaro Beats Ozempic in Head-to-Head Study

newser.com/story/368559/mounjaro-beats-ozempic-in-head-to-head-study.html

Mounjaro wins bragging rights over Ozempic in a new weight-loss study—though it's one that was funded by the maker of Mounjaro. Researchers found that those taking tirzepatide, marketed as Mounjaro and Zepbound, lost about 20% of their body weight over 72 weeks, according to the study…

This story appeared on newser.com, 2025-05-13 13:49:05.182000.